MedCity News April 29, 2024
Ono Pharmaceutical’s acquisition of Deciphera Pharmaceuticals adds to a cancer drug pipeline that already spans multiple modalities. Deciphera develops drugs that target the on-off switch of enzymes that drive cancer cell growth.
Ono Pharmaceutical is expanding its scope in oncology with a $2.4 billion deal to buy Deciphera Pharmaceutical, a company that has one commercialized cancer therapy and a drug pipeline that includes a late-stage candidate on track for an FDA submission.
According to deal terms announced Monday, Japan-based Ono has agreed to pay $25.60 in cash for each share of Deciphera. That price represents a 74.7% premium to Deciphera’s closing stock price on Friday and a 68.8% premium to the stock’s average price over the past month. Shares of...